print_label | resize_label

About Us

Spirogen is a member of the AstraZeneca group. We have developed a potent and flexible class of ADC payload based on our proprietary PBD technology.

PBD payloads have been clinically validated in multiple partnered programs.

We have developed a third generation of PBD payload with marked improvements in terms of activity, ease of manufacture, therapeutic index and available quality control assays.

We collaborate closely with licensors of the PBD ADC technology, providing expertise in the selection of the optimal payload for a particular application.

Spirogen is a Premier Antibody-Drug Conjugate Partner


POTENT WARHEAD

 

  • Pyrrolobenzodiazepines (PBDs) are amongst the most cytotoxic agents known; ideally suited for antibody-drug conjugation
  • Unique mechanism of action retains activity against cancer stem cells
  • Compatible with multiple different linker and conjugation technologies

 


UNIQUE ADC PARTNER

 

  • Significant experience working with multiple partners
  • Years of experience with multiple non-specific and site-specific conjugation technologies
  • Able to build on collective experience of Spirogen/MedImmune team with multiple warheads, antibodies and linker technologies

 


LICENSES AVAILABLE TO SELECT PARTIES

 

  • MedImmune/AstraZeneca acquired Spirogen in 2013
  • We are considering flexible deal structures to enable future development success

 

Key Components of Antibody-Drug Conjugates

 

1

ANTIBODY

  • High tumor specificity
  • Internalization

 

 

2

PAYLOAD

  • Cytotoxic Drug (Warhead)
    • High potency
    • Able to attach linker
    • Soluble
  • Linker
    • Stable in circulation
    • Cleaved inside target cell
    • Stable upon storage